<?xml version="1.0" encoding="UTF-8"?>
<p>The hepatocyte toxicity triggered by AAV capsid immune responses is clinically asymptomatic and resembles, to a certain extent, autoimmune hepatitis 
 <sup>
  <xref rid="ref-131" ref-type="bibr">131</xref>
 </sup>. As such, the use of steroids as the first line of treatment is reasonable. Data suggest that steroids are most effective if initiated within 48 hours after increase of liver enzymes and/or decrease in transgene expression and should be continued for 8–12 weeks 
 <sup>
  <xref rid="ref-99" ref-type="bibr">99</xref>, 
  <xref rid="ref-128" ref-type="bibr">128</xref>
 </sup>. This strategy has been effective in most studies. However, in the Shire-sponsored study, therapeutic levels of FIX (peak at 60%) were achieved in the high-dose cohort (3 × 10 
 <sup>12</sup> vg/kg), but the duration of expression was transient and reduction in expression coincided with increased ALT 
 <sup>
  <xref rid="ref-103" ref-type="bibr">103</xref>
 </sup>. In an AAV-8-FIX clinical study at the Children’s Hospital of Philadelphia, three subjects were infused at doses of 1 to 2 × 10 
 <sup>12</sup> vg/kg and all developed an immune response to the vector capsid that was not controlled by immunosuppression, resulting in loss of transgene expression 
 <sup>
  <xref rid="ref-94" ref-type="bibr">94</xref>
 </sup>. Alternative immunosuppression regimens may be required 
 <sup>
  <xref rid="ref-132" ref-type="bibr">132</xref>
 </sup>.
</p>
